Abstract
Adoptive transfer of T cells expressing a transgenic T cell receptor (TCR) has the potential to revolutionize immunotherapy of infectious diseases and cancer. However, the generation of defined TCR-transgenic T cell medicinal products with predictable in vivo function still poses a major challenge and limits broader and more successful application of this ‘living drug’. Here, by studying 51 different TCRs, we show that conventional genetic engineering by viral transduction leads to variable TCR expression and T cell product functionality as a result of interference with the endogenous TCR, variable transgene copy numbers, and un-targeted transgene integration. In contrast, CRISPR/Cas9-mediated TCR gene editing enables defined, targeted TCR insertion with concomitant knock-out of the endogenous receptor. Thereby, T cell products display more homogenous and physiological TCR expression which results in increased functionality and – importantly – less variable in vivo T cell responses in comparison to conventionally generated T cells. Hence, targeted TCR gene editing increases the predictability of TCR-transgenic T cell product function, which represents a crucial aspect for clinical application in adoptive T cell immunotherapy.
BRIEF SUMMARY Safer, more functional and predictable transgenic T cell products for immunotherapy can be generated via CRISPR/Cas9-mediated targeted TCR engineering
Competing Interest Statement
D.H.B. is co-founder of STAGE Cell Therapeutics GmbH (now Juno Therapeutics a Bristol-Myers Squibb Company) and T Cell Factory B.V. (now Kite a Gilead Company). D.H.B. has a consulting contract with and receives sponsored research support from Juno Therapeutics.
Funding Statement
This work was mainly supported by the German Center for Infection Research (DZIF).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent was obtained from the donors, and usage of the blood samples was approved according to national law by the local Institutional Review Board (Ethikkommission der Medizinischen Fakultät der Technischen Universität München).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
CONFLICT OF INTEREST D.H.B. is co-founder of STAGE Cell Therapeutics GmbH (now Juno Therapeutics a Bristol-Myers Squibb Company) and T Cell Factory B.V. (now Kite a Gilead Company). D.H.B. has a consulting contract with and receives sponsored research support from Juno Therapeutics.
Data Availability
All data generated or analyzed during this study are included in this article and its supplementary information files. Additional raw data are available from the corresponding authors upon reasonable request.
